Brief: Immix Biopharma Announces Dosing Of First Two Patients With Experimental Drug For Advanced Cancer
07/02/2023 13:32
Feb 7 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA ANNOUNCES DOSING OF FIRST 2 PATIENTS IN
ITS
IMX-110 + BEIGENE/NOVARTIS ANTI-PD-1 TISLELIZUMAB PHASE 1B/2A
COMBINATION CLINICAL TRIAL IN PATIENTS WITH ADVANCED CANCER
* IMMIX BIOPHARMA INC - INITIAL DATA ANTICIPATED IN 1H 2023
Source text for Eikon: ID:nGNE2SD8W2
Further company coverage: IMMX.O
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary